Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston Scientific plea deal

This article was originally published in The Gray Sheet

Executive Summary

Firm's Guidant subsidiary will plead guilty to two misdemeanor charges related to its failure to include information in product safety reports to FDA, Boston Scientific announces Nov. 6. The plea is part of a settlement with the Department of Justice stemming from an investigation launched in 2005 by the U.S. Attorney's Office in Minneapolis (1"The Gray Sheet" Oct. 31, 2005). The federal investigators scrutinized whether then-independent Guidant made timely disclosures to FDA regarding malfunctions of its Ventak Prizm 2, Contak Renewal and Contak Renewal 2 implantable defibrillators. The products were the subject of a series of product safety advisories in 2005 amid criticism of industry and FDA processes for disclosing, tracking and responding to adverse event data. As part of the agreement, Boston Scientific will pay $296 million. On the same day, Boston Scientific disclosed to the Securities and Exchange Commission that it received a subpoena on Sept. 25 from the Health and Human Services Office of Inspector General requesting information relating to contributions made by the company's cardiac rhythm management division "to charities with ties to physicians or their families." The firm says it is "working with the government to understand the scope of the subpoena.

You may also be interested in...

Judge Delays Acceptance Of Boston Scientific Guilty Plea In Guidant ICD Case

Boston Scientific's hopes of putting one significant source of Guidant-inherited legal troubles behind it hit at least a short delay last week

DOJ Prosecutors Turn Attention To Manufacturing, Safety Issues

The Department of Justice is increasingly tackling issues of FDA compliance beyond the standard sales and marketing fare, pursuing cases related to device manufacturing, adverse event reporting and even product labeling, recent cases suggest

Cardiac Rhythm Management Firms Targeted By DoJ Fraud Investigation

Subpoenas served to Guidant, Medtronic and St. Jude Medical by the U.S. Department of Justice appear to be investigating potential improper inducements to increase sales of pacemakers and ICDs


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts